Trump’s tariffs will likely affect cancer drugs and devices—and may deepen drug shortages

Elahere shows survival benefit in long-term analysis for ovarian cancer patients in phase III study

AbbVie announced the final analysis of the confirmatory phase III MIRASOL trial evaluating the efficacy and safety of Elahere in women with folate receptor alpha-positive platinum-resistant ovarian cancer compared to chemotherapy.

March 21, 2025

Vol.51 No.11

Drugs & Targets

FDA approves Tevimbra + chemo for advanced ESCC

FDA approved Tevimbra (tislelizumab-jsgr), in combination with platinum-containing chemotherapy, for the first-line treatment of adults with unresectable or metastatic esophageal squamous cell carcinoma whose tumors express PD-L1 (≥1).

March 07, 2025

Vol.51 No.09

Podcast

In The Headlines: What’s up with the U.S. cancer incidence rate?

In this episode of In the Headlines, Paul Goldberg, publisher of The Cancer Letter, and Jacquelyn Cobb, associate editor, talk about controversial data cited in Trump’s “Make American Healthy Again” executive order that claims that the U.S. has the highest age-standardized incidence rate of cancer globally. But where did that data come from?

February 26, 2025

Vol.51 No.07

News Analysis

Trump executive order to “Make America Healthy Again” cites questionable data from Wuhan
White House cites paper in pay-to-play journal claiming that U.S. has highest age-standardized incidence rate of cancer

Cancer data quoted in President Trump’s executive order last week have raised eyebrows among experts in cancer epidemiology.

Opdivo + chemo improves OS in resectable lung cancer, phase III study shows

Bristol Myers Squibb announced the final analysis of overall survival from the phase III CheckMate-816 study, which evaluated Opdivo (nivolumab) in combination with platinum-doublet chemotherapy as a neoadjuvant treatment for adult patients with resectable (tumors ≥ 4 cm or node positive) non-small cell lung cancer.

February 21, 2025

Vol.51 No.07

In Brief

Daniel Nomura named editor-in-chief of Molecular Cancer Therapeutics

Daniel K. Nomura was named editor-in-chief of Molecular Cancer Therapeutics, one of the 10 journals published by the American Association for Cancer Research.

February 14, 2025

Vol.51 No.06

Trump’s tariffs will likely affect cancer drugs and devices—and may deepen drug shortages

YOU MAY BE INTERESTED IN

Elahere shows survival benefit in long-term analysis for ovarian cancer patients in phase III study

FDA approves Tevimbra + chemo for advanced ESCC

In The Headlines: What’s up with the U.S. cancer incidence rate?

Trump executive order to “Make America Healthy Again” cites questionable data from Wuhan
White House cites paper in pay-to-play journal claiming that U.S. has highest age-standardized incidence rate of cancer

Opdivo + chemo improves OS in resectable lung cancer, phase III study shows

Daniel Nomura named editor-in-chief of Molecular Cancer Therapeutics

Renew today!

Subscriber content

Never miss an issue!

Login

Trump’s tariffs will likely affect cancer drugs and devices—and may deepen drug shortages

YOU MAY BE INTERESTED IN

Elahere shows survival benefit in long-term analysis for ovarian cancer patients in phase III study

FDA approves Tevimbra + chemo for advanced ESCC

In The Headlines: What’s up with the U.S. cancer incidence rate?

Trump executive order to “Make America Healthy Again” cites questionable data from WuhanWhite House cites paper in pay-to-play journal claiming that U.S. has highest age-standardized incidence rate of cancer

Opdivo + chemo improves OS in resectable lung cancer, phase III study shows

Daniel Nomura named editor-in-chief of Molecular Cancer Therapeutics

Never miss an issue!

Login

Trump executive order to “Make America Healthy Again” cites questionable data from Wuhan
White House cites paper in pay-to-play journal claiming that U.S. has highest age-standardized incidence rate of cancer